BIO-TECHNE executive reports initial share and award holdings

BIO-TECHNE Corp executive Steven C. Crouse, President – Diagnostics & Spatial Biology, filed an initial Form 3 reporting his equity holdings.

Accepted by SEC EDGAR 03/04/2026 - 06:47 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BIO-TECHNE Corp executive Steven C. Crouse, President – Diagnostics & Spatial Biology, filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units, stock options and common stock, including 6,529 restricted stock units and 5,894 shares of common stock.

The footnotes explain that each restricted stock unit represents a right to receive one share of Bio-Techne common stock, with multiple RSU and option grants vesting in scheduled installments between 2025 and 2029. The filing does not show any new share purchases or sales, only existing awards and their vesting timelines.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Crouse Steven C.

Role President - Diag & Spatial Bi

Type	Security	Shares	Price	Value
Holding	Restricted Stock Units	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Stock Option (right to buy)	--	--	--
Holding	Common Stock	--	--	--

Holdings: Restricted Stock Units — 15,033 contracts (Direct); Stock Option (right to buy) — 109,142 contracts (Direct); Common Stock — 5,894 shares (Direct)

Footnotes (13)

F1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F2. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.
F3. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
F4. 1,379 restricted stock units vest on 8/15/2026.
F5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
F6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
F7. 100% vested.
F8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
F9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
F10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
F11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
F12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
F13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BIO-TECHNE (TECH) Form 3 for Steven C. Crouse report?

The Form 3 reports Steven C. Crouse’s existing equity holdings in BIO-TECHNE, including restricted stock units, stock options and common stock. It establishes his baseline ownership as an officer, detailing positions and vesting schedules rather than showing any new stock purchases or sales.

How many BIO-TECHNE (TECH) common shares does Steven C. Crouse report on Form 3?

Steven C. Crouse reports direct ownership of 5,894 shares of BIO-TECHNE common stock. This figure reflects his baseline common share position as of the Form 3 date and is separate from his restricted stock units and stock option awards disclosed in the filing.

What restricted stock unit holdings are disclosed for BIO-TECHNE (TECH) executive Steven C. Crouse?

The Form 3 shows several restricted stock unit awards, including a position of 6,529 restricted stock units. Footnotes explain that each restricted stock unit equals one share of BIO-TECHNE common stock, with different grants vesting on specified dates between 2025 and 2028.

How do the stock options reported in BIO-TECHNE (TECH) Form 3 vest for Steven C. Crouse?

The filing lists multiple stock option grants with distinct vesting schedules from 2023 through 2029. Footnotes describe option tranches, such as options to purchase 6,140 shares vesting on each of August 15, 2023, 2024, 2025 and 2026, plus additional multi-year grants.

Does the BIO-TECHNE (TECH) Form 3 for Steven C. Crouse show any stock purchases or sales?

The Form 3 does not show any new stock purchases or sales. All transactions are coded as holdings, with transaction direction marked unknown. The document simply records existing restricted stock units, stock options and common shares along with their vesting schedules.

What vesting dates are highlighted for BIO-TECHNE (TECH) restricted stock units in this Form 3?

Footnotes highlight several vesting dates, including May 1, 2026 and 2027, June 2, 2026–2028, and August 15, 2026–2028. These dates apply to different restricted stock unit grants, specifying when Crouse becomes entitled to receive BIO-TECHNE common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Crouse Steven C.

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

55413

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President - Diag & Spatial Bi

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,894	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽²⁾	⁽²⁾	Common Stock	1,588	⁽¹⁾	D
Restricted Stock Units	⁽³⁾	⁽³⁾	Common Stock	1,800	⁽¹⁾	D
Restricted Stock Units	⁽⁴⁾	⁽⁴⁾	Common Stock	1,379	⁽¹⁾	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	3,737	⁽¹⁾	D
Restricted Stock Units	⁽⁶⁾	⁽⁶⁾	Common Stock	6,529	⁽¹⁾	D
Stock Option (right to buy)	⁽⁷⁾	04/01/2028	Common Stock	3,856	$97.13	D
Stock Option (right to buy)	⁽⁷⁾	08/06/2028	Common Stock	19,032	$120.46	D
Stock Option (right to buy)	⁽⁸⁾	08/15/2029	Common Stock	24,560	$94.52	D
Stock Option (right to buy)	⁽⁹⁾	08/15/2030	Common Stock	12,649	$84.61	D
Stock Option (right to buy)	⁽¹⁰⁾	05/01/2031	Common Stock	7,327	$73.46	D
Stock Option (right to buy)	⁽¹¹⁾	08/15/2034	Common Stock	17,133	$74.91	D
Stock Option (right to buy)	⁽¹²⁾	06/02/2035	Common Stock	5,434	$48.61	D
Stock Option (right to buy)	⁽¹³⁾	08/15/2035	Common Stock	19,151	$53.6	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

2. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.

3. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.

4. 1,379 restricted stock units vest on 8/15/2026.

5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.

6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.

7. 100% vested.

8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.

10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.

11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.

12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.

13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney filed herewith.	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR